KINDLIN-1 AS A MARKER OF SENSITIVITY TO EGFR/RAS PATHWAY INHIBITORS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20230184775A1
SERIAL NO

17925008

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention concerns an ex vivo method for selecting patient having cancer as eligible to EGFR/RAS pathway inhibitor therapy, an EGFR/RAS pathway inhibitor for use for treating cancer in a patient, and a method for prognosis cancer outcome or progression.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUT CURIE26 RUE D'ULM PARIS 75248

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Driouch, Keltouma Paris, FR 3 17
Lidereau, Rosette Paris, FR 7 37

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation